Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Investor Presentation (November 2019)

22 slides from Neuroscientific Biopharmaceuticals's investor presentation, Nov 19, 2019

  1. Slide 1: Novel Drug Therapies for Neurodegenerative Conditions

    For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  3. Slide 3: Corporate Overview

    CORPORATE OVERVIEW For personal use only • Completed IPO listing on the ASX on the 27 July 2018 • Lead candidate funded through to completion of Phase I (mid- late 2020) • Lead indication – Alzheimer’s Disease, Secondary indication - ASX code NSB Optic Neuropathy (Glaucoma, Shares on issue 78.3M etc

  4. Slide 4: Leadership Team

    LEADERSHIP TEAM For personal use only Co-founder of ResApp Health 13+ years experience Founding director of 20 years’ experience in Ltd (ASX.RAP), Imugene Ltd commercialising medical Actinogen Medical corporate advisory and (ASX:IMU) devices and pharmaceuticals (ASX:ACW) an advanced company director

  5. Slide 5: Treatment Markets with Unmet Need

    TREATMENT MARKETS WITH UNMET NEED For personal use only NEURODEGENERATIVE OPTIC NEUROPATHIES DISEASES (Alzheimer’s, etc) (Glaucoma, etc) 48M people globally 5% of population have dementia suffer vision loss due to 70% of dementias damaged optic nerve Alzheimer’s disease 60M people US $818B global af

  6. Slide 6: Alzheimer's Disease: The need for novel therapeutics

    ALZHEIMER’S DISEASE: The need for novel therapeutics Frequency of For personal use only Alzheimer’s disease • Drugs targeting the beta-amyloid protein have all could be reduced by failed in late-stage clinical trials… 50% if the onset could be delayed by • Pathology of Alzheimer’s disease still not

  7. Slide 7: Lead Candidate: EmtinB

    LEAD CANDIDATE: EMTINB For personal use only NOVEL • Modeled on Metallothionein (MT-II) - a well known neuroprotective and neurogenerative compound, with EmtinB showing superior drug properties • MOA: Binds LRP-1/2 receptors and a) activates intracellular signaling pathways (activation of ERK, Akt,

  8. Slide 8: Development of EmtinB

    DEVELOPMENT OF EMTINB For personal use only MT-II STRUCTURE EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain • 61 amino acid length • 14 amino acid length • EmtinB is manufactured as tetrameric • Binds divalent metal ions • Isolated from the β-domain of dendrimer, in which four monomer • Di

  9. Slide 9: EmtinB Mechanism of Action: Binding LRP-1 receptor

    EMTINB MECHANISM OF ACTION: Binding LRP-1 receptor For personal use only

  10. Slide 10: MOA2: Microglia Induced Neuroinflammation in Alzheimer's Disease

    MOA2: Microglia Induced Neuroinflammation in Alzheimer’s Disease For personal use only ▹Identification of a Unique Microglia Type Associated with Alzheimer’s Disease (Disease Associated Microglia) ▹DAM Are Localized near AD Plaques (2017, Cell 169, 1276– 1290). DAM are located within the cortex, but

  11. Slide 11: Preclinical Data to Date

    PRECLINICAL DATA TO DATE For personal use only

  12. Slide 12: EmtinB Scientific Data: Increases survival of neurons

    EMTINB SCIENTIFIC DATA Increases survival of neurons For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: ALZHEIMER’S MODEL

  13. Slide 13: EmtinB Scientific Data: Preclinical axonal regeneration

    EMTINB SCIENTIFIC DATA Preclinical axonal regeneration For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: INJURY MODEL SPINAL CORD: INJURY MODEL

  14. Slide 14: Most recent data - Spinal cord injury model

    EMTINB SCIENTIFIC DATA Most recent data - Spinal cord injury model • For personal use only Primary neurons isolated from spinal cord tissue of adult rats • EmtinB (30µg/mL) neuron regeneration >300% vs. untreated control • EmtinB (30µg/mL) neuron regeneration >2x Copaxon®; marketed drug for Multiple

  15. Slide 15: Preclinical studies: animal models

    EMTINB SCIENTIFIC DATA Preclinical studies: animal models For personal use only Plasma profile: was detected 10-min after administration and Slowed progression of disease remained detectable up to the 24-hour time point (memory impairment) by >80% in Crosses the blood brain barrier, detected in CSF

  16. Slide 16: Supporting Scientific Data: Regenerating the optic nerve

    SUPPORTING SCIENTIFIC DATA Regenerating the optic nerve For personal use only • Precursor to EmtinB (MT-II) stimulated regenerative growth of optic (4 weeks after posttransection surgery, n=16) • Promotes axonal regeneration through an inhibitory environment in vivo Optic Nerve Growth No Treatment T

  17. Slide 17: Supporting Scientific Data: Regenerating the optic nerve

    SUPPORTING SCIENTIFIC DATA Regenerating the optic nerve For personal use only • Precursor to EmtinB (MT-II) stimulated regenerative growth of optic • data demonstrates the ability of labeled EmtinB to penetrate the retina and optic nerve of the rabbit eye with no side effects • Next phase of the pro

  18. Slide 18: Strategic Partnerships and Affiliated Network

    STRATEGIC PARTNERSHIPS AND AFFILIATED NETWORK For personal use only

  19. Slide 19: EmtinB Development Schedule

    EMTINB DEVELOPMENT SCHEDULE For personal use only 2019 2019 2019 2019 2020 2020 2020 2020 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Alzheimer’s disease indication Preclinical safety & toxicology studies Additional AD animal efficacy study (CVN AD model) Phase I clinical study Ophthalmology indication Preclinical safe

  20. Slide 20: Key Milestones

    KEY MILESTONES For personal use only DEC -19 OCT -19 Results on efficacy Report on ocular tissue study in glaucoma pig distribution study in model rabbits. NOV -19 FEB -20 Results on additional Expected conclusion of efficacy study in CVN safety & toxicity studies Alzheimer’s model

  21. Slide 21: Novel Drug Therapies for Neurodegenerative Conditions

    For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS

  22. Slide 22: Dr William Harold Clough AO, OBE, FTS

    For personal use only Dr William Harold Clough AO, OBE, FTS Founder of Clough Engineering Founder of McRae Investments Founder of Neuroscientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals — Investor Presentation (November 2019) on 6ix